Editas Medicine
11 Hurley Street
Cambridge
MA
02141
United States
Tel: 617 401 9000
Website: https://www.editasmedicine.com/
Email: info@editasmed.com
About Editas Medicine
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
Stock Symbol: EDIT
Stock Exchange: NASDAQ
246 articles about Editas Medicine
-
Bayer isn't the only company to announce changes to its leadership team this morning. Editas, Biogen, Takeda, Merck and Vedere Bio also announced leadership changes.
-
On Thursday, Intellia announced it had paid Rewrite shareholders $45 million upfront. Additionally, the transaction involved a transfer of $155 million in the form of Intellia common stock and cash.
-
Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview and update at the 40th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 12, 2022, at 10:30 a.m. ET
-
Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia
12/20/2021
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for EDIT-301 for the treatment of transfusion-dependent beta thalassemia (TDT), enabling the Company to initiate a Phase 1/2 clinical study of EDIT-301 in TDT patients.
-
Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting
12/12/2021
Editas Medicine, Inc., a leading genome editing company, reported in vitro and in vivo preclinical data on the enhanced tumor killing capacity of two modified induced pluripotent stem cell -derived natural killer cell therapies using Editas Medicine’s proprietary AsCas12a gene editing.
-
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
-
Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting
11/12/2021
Editas Medicine, Inc., a leading genome editing company, announced preclinical data on its progress in the development of novel engineered induced pluripotent stem cell -derived natural killer cells for the treatment of cancer.
-
Editas Medicine Announces Third Quarter 2021 Results and Business Updates
11/8/2021
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the third quarter of 2021.
-
Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and Cancer at the ASH Annual Meeting and Exposition
11/4/2021
Editas Medicine, Inc., a leading genome editing company, announced that two scientific abstracts have been accepted for presentation at the 63rd Annual Meeting and Exposition of the American Society of Hematology, being held in Atlanta and virtually, December 11-14, 2021.
-
Editas Medicine Names Bernadette Connaughton to Board of Directors
10/28/2021
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Bernadette Connaughton to its Board of Directors.
-
Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update
10/25/2021
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, November 8, 2021, at 8:00 a.m. ET to provide a corporate update and results for the third quarter of 2021.
-
Clinical Catch-Up: October 18-22
10/25/2021
It was yet another busy week for clinical trial news. Here’s a look. -
The experimental drug, NTLA-2001, is being developed for the treatment of transthyretin (ATTR) amyloidosis.
-
Clinical Data from Editas Medicine’s Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual Congress
10/20/2021
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that an abstract featuring initial clinical data from the BRILLIANCE clinical trial of EDIT-101 has been selected for an oral presentation at the 2021 European Society of Gene and Cell Therapy (ESGCT) Annual Congress being held virtually October 19 – 22, 2021.
-
Biopharma companies recognized that developing a therapy is merely the beginning of what is needed to connect patients with sickle cell disease to next-level therapies.
-
Editas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting
10/7/2021
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the Company will present preclinical data on its progress in the development of cell therapy medicines for the treatment of cancer at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting being held in Washington, D.C., and virtually, November 10-14, 2021.
-
EDIT-101 targets a disease-causing mutation in the CEP290 gene that causes degeneration in ocular photoreceptor cells, which are critical for normal vision.
-
Editas Medicine to Present at Chardan’s 5th Annual Genetic Medicines Conference
9/30/2021
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, will present at Chardan’s 5th Annual Genetic Medicines Conference on Monday, October 4, 2021 at 8:30 a.m. ET.
-
Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10
9/29/2021
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced positive initial clinical data from the ongoing, open label Phase 1/2 BRILLIANCE clinical trial of EDIT-101.
-
Editas Medicine Names Emma Reeve to Board of Directors
9/8/2021
Editas Medicine, Inc., a leading genome editing company, announced that it has appointed Emma Reeve to its Board of Directors.